corticosteroids - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.98 [0.93, 1.02]< 10%5 studies (5/-)85.0 %some concernnot evaluable moderatecrucial-
deaths 0.92 [0.84, 1.00]< 120%10 studies (10/-)97.3 %some concernlow moderatecrucial-
hospitalization or death 0.39 [0.09, 1.67]< 10%1 study (1/-)89.7 %lownot evaluable highcrucial-
clinical deterioration 0.67 [0.44, 1.03]< 10%2 studies (2/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.04 [0.67, 1.62]> 10%1 study (1/-)57.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.22 [0.83, 1.77]> 10%2 studies (2/-)84.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.28 [0.84, 1.96]> 10%1 study (1/-)87.2 %lownot evaluable highimportant-
clinical improvement (7-day) 0.92 [0.51, 1.66]> 10%1 study (1/-)39.1 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.04 [0.67, 1.62]> 10%1 study (1/-)57.5 %some concernnot evaluable moderateimportant-
death or ventilation 0.92 [0.84, 1.00]< 10%2 studies (2/-)97.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.19 [0.86, 1.64]> 137%2 studies (2/-)85.7 %some concernnot evaluable moderateimportant-
hospitalization 1.92 [0.47, 7.89]< 10%1 study (1/-)18.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.82 [0.67, 0.99]< 10%4 studies (4/-)97.8 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 4.89 [1.15, 20.79]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-
viral clearance 1.78 [1.06, 3.00]> 10%1 study (1/-)98.5 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.78 [1.06, 3.00]> 10%1 study (1/-)98.5 %some concernnot evaluable moderateimportant-
ICU admission 1.00 [0.13, 7.45]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatenon important-
recovery 1.25 [0.71, 2.22]> 10%1 study (1/-)78.2 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.53 [0.17, 1.62]< 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
superinfection 0.91 [0.66, 1.25]< 10%2 studies (2/-)72.5 %some concernnot evaluable moderateimportant-
adverse events 0.82 [0.43, 1.57]< 10%1 study (1/-)72.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.